Tri-Sprintec

Acne Vulgaris, moderate Vulvovaginal atrophy, Hot flashes + 9 more

Treatment

9 FDA approvals

20 Active Studies for Tri-Sprintec

What is Tri-Sprintec

Norgestimate

The Generic name of this drug

Treatment Summary

Ethinylestradiol is a synthetic form of the hormone estrogen. It was developed in 1938 with the goal of creating a form of estrogen that was more easily absorbed by the body. It is commonly used in birth control pills and was approved by the FDA in 1943.

Ortho Tri Cyclen

is the brand name

image of different drug pills on a surface

Tri-Sprintec Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ortho Tri Cyclen

Norgestimate

1989

113

Approved as Treatment by the FDA

Norgestimate, commonly known as Ortho Tri Cyclen, is approved by the FDA for 9 uses which include Postmenopausal Osteoporosis and severe menopausal vulvovaginal atrophy .

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

severe menopausal vulvovaginal atrophy

Used to treat severe menopausal vulvovaginal atrophy in combination with Estradiol

Oral Contraceptives

Used to treat Oral Contraceptives in combination with Ethinylestradiol

Acne Vulgaris

Used to treat moderate Acne vulgaris in combination with Ethinylestradiol

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

moderate Vulvovaginal atrophy

Used to treat moderate Vulvovaginal atrophy in combination with Estradiol

Hot flashes

Used to treat Menopause in combination with Estradiol

moderate Menopausal Vasomotor Symptoms

Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol

Menopause

Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol

Effectiveness

How Tri-Sprintec Affects Patients

Ethinylestradiol is a type of estrogen medication taken once a day. It helps to reduce luteinizing hormone and gonadotrophic hormones, which can stop ovulation and reduce the blood supply to the endometrium. It is generally considered safe with a low risk for side effects, however patients should be warned about potential risks of clotting.

How Tri-Sprintec works in the body

Ethinylestradiol is a synthetic estrogen. It is used in oral contraceptives to prevent pregnancy. It does this by suppressing ovulation, thickening cervical mucus, and blocking changes to the endometrium that would allow for fertilization. It also decreases luteinizing hormone, reducing the amount of blood vessels in the endometrium and increasing sex hormone binding globulin.

When to interrupt dosage

The measure of Tri-Sprintec is dependent upon the diagnosed circumstance, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The amount of dosage is contingent upon the application procedure as elucidated in the table underneath.

Condition

Dosage

Administration

Polycystic Ovarian Syndrome

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

severe menopausal vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menopause

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Osteoporosis, Postmenopausal

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Oral Contraceptives

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menorrhagia

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hirsutism

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Menopausal Vasomotor Symptoms

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hot flashes

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Acne Vulgaris

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Dysmenorrhea

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Warnings

Tri-Sprintec has twenty-six contraventions, and should not be utilized when afflicting any of the conditions enumerated in the table beneath.

Tri-Sprintec Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Breast Cancer

Do Not Combine

high risk of arterial thrombotic disease

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Hypersensitivity

Do Not Combine

Venous Thrombosis

Do Not Combine

Pulse Frequency

Do Not Combine

estrogen-sensitive cancer

Do Not Combine

Metrorrhagia

Do Not Combine

Liver Neoplasms

Do Not Combine

There are 20 known major drug interactions with Tri-Sprintec.

Common Tri-Sprintec Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Norgestimate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Norgestimate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Norgestimate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Norgestimate.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Norgestimate.

Tri-Sprintec Toxicity & Overdose Risk

Women who overdose on Yaz may have symptoms such as bleeding, nausea, vomiting, breast pain, abdominal discomfort, drowsiness, and fatigue. Treatment for an overdose should include monitoring potassium, sodium levels, and signs of acidosis, as well as providing supportive care.

Tri-Sprintec Novel Uses: Which Conditions Have a Clinical Trial Featuring Tri-Sprintec?

38 active studies are currently being conducted to determine the efficacy of Tri-Sprintec in providing Folate supplementation therapy, Premenstrual Dysphoric Disorder and Menopausal relief.

Condition

Clinical Trials

Trial Phases

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Acne Vulgaris

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Menopause

0 Actively Recruiting

Polycystic Ovarian Syndrome

7 Actively Recruiting

Not Applicable, Phase 1

moderate Menopausal Vasomotor Symptoms

0 Actively Recruiting

Hirsutism

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

moderate Vulvovaginal atrophy

0 Actively Recruiting

Menorrhagia

3 Actively Recruiting

Phase 1, Phase 2, Not Applicable

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Tri-Sprintec Reviews: What are patients saying about Tri-Sprintec?

5

Patient Review

5/26/2022

Tri-Sprintec for Birth Control

I've only been taking Tri-Sprintec for two weeks, and I'm already really pleased with it. No significant side effects yet—just some breast tenderness. I was hesitant to try it after reading some of the negative reviews online, but I'm glad I did. It's affordable and works well, so I would definitely recommend it.

5

Patient Review

7/15/2022

Tri-Sprintec for Abnormally Long or Heavy Periods

I had sex with my boyfriend and he came inside of me. I'm thankful that I was on this combination birth control, because my period started a week later. The only downside is that my period lasted for weeks, but I'm still grateful that there was no pregnancy.

4

Patient Review

2/15/2022

Tri-Sprintec for Abnormally Long or Heavy Periods

Overall, this pill has been helpful in keeping me from getting pregnant and my period regular. However, the negative side effects can't be ignored. I've experienced moodiness, depression, headaches, and nausea while on this medication.

4

Patient Review

12/1/2021

Tri-Sprintec for Birth Control

I started taking tri sprintec again last month and had awful flu-like symptoms for the first 1-2 weeks. After that, though, I felt great. I'm hoping it will help with my hormonal acne but so far haven't seen much improvement.

3.7

Patient Review

1/4/2022

Tri-Sprintec for Birth Control

I began taking this medication after coming off an implant. This decision was the worst decision. The side effects were worse than the implant. I gained about 30 lbs in about 4 months while continuing to be super active as I have always been. Overall, I did not feel like myself. I did not suffer from any depression or mood changes, but the weight was too much for me.

3.3

Patient Review

8/2/2021

Tri-Sprintec for Birth Control

I've been on this birth control for a while now, and it's made me put on a lot of weight. I'm also always in a bad mood, which is really tough to deal with. On the bright side, my period was regular until I tried skipping the sugar pill; now it's all over the place again.

3.3

Patient Review

12/21/2020

Tri-Sprintec for Birth Control

I'm on my second pack of this birth control, and I think my body is still adjusting to it. I've been feeling bloated, have had some irregular spotting, and my breasts are tender. I'm hoping these side effects will go away soon.

3.3

Patient Review

8/5/2022

Tri-Sprintec for Birth Control

I went to the hospital because of brown discharge. I didn't know what it was, and I bled a lot of the time. Now I have these crazy headaches. It also gave me a yeast infection. This is the worst treatment I've ever had.

3

Patient Review

1/24/2022

Tri-Sprintec for Abnormally Long or Heavy Periods

Within a few months of taking this birth control, I stopped feeling emotions. I also got two yeast infections, which were both very painful experiences.

3

Patient Review

9/24/2022

Tri-Sprintec for Birth Control

While this birth control did decrease my chances of getting pregnant, the negative impacts on my mental and physical health were not worth it. I gained a lot of weight, felt constantly bloated and terrible, experienced anxiety and depression, and developed cystic acne.

2.7

Patient Review

4/12/2022

Tri-Sprintec for Birth Control

I took this medication for a full year as directed, but I still got pregnant.

2.3

Patient Review

2/21/2022

Tri-Sprintec for Abnormally Long or Heavy Periods

I experienced some nasty side effects like headaches, gas, and breast tenderness. Plus, I felt really anxious for no reason.

2.3

Patient Review

6/7/2022

Tri-Sprintec for Painful Periods

I started taking this kind of birth control as recommended by my gynecologist, but just a few days in I started vomiting for three days straight. I went to see a doctor and they told me that the pill was making me sick. I've since changed to another brand of birth control in the hopes that it won't have any negative side effects. All I want is to have less painful periods and be protected from pregnancy.

2

Patient Review

9/14/2022

Tri-Sprintec for Birth Control

This birth control almost killed me. It gave me AGEP (very rare allergic reaction). I’d suggest googling the effects of AGEP and seriously seeking another form of b/c. I went through the worst pain of my life and it took months to recover.

1

Patient Review

12/27/2020

Tri-Sprintec for Birth Control

I started feeling numb and tingly all over my body yesterday, after only taking this pill for the first time. I'm also wondering if it could be a side effect from coming off my depo shot. If anyone has any answers or insights, please let me know.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tri-sprintec

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Tri-Sprintec a good birth control?

"The Tri-Sprintec is just as effective as any other birth control pill. If you use it perfectly, then it is 99.7% effective, but if you use it like a regular person, then it is only 93% effective."

Answered by AI

What does Tri-Sprintec do to your body?

"This medication contains a combination of 2 hormones, a progestin, and an estrogen, which are used to prevent pregnancy. In addition to preventing pregnancy, birth control pills may also make your periods more regular, decrease blood loss, and painful periods, decrease your risk of ovarian cysts, and also treat acne."

Answered by AI

What kind of birth control is Tri-Sprintec?

"Norgestimate is a synthetic progestin derived from 19-nor-testosterone.

The text is discussing Tri-Sprintec, a combination oral contraceptive containing the progestational compound norgestimate, and the estrogenic compound ethinyl estradiol. Norgestimate is a synthetic progestin derived from 19-nor-testosterone."

Answered by AI

Will Tri-Sprintec make me gain weight?

"If you research online, you'll mostly find that women complain about gaining weight from birth control pills, not losing it. Tri-Sprintec doesn't have any ingredients known to cause weight loss; but, you can still lose weight through diet and exercise while taking this pill."

Answered by AI

Clinical Trials for Tri-Sprintec

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Lindus Health - DECENTRALIZED STUDY in Boston, United States.

Neurostimulation for Heavy Menstrual Bleeding

14 - 45
Female
Boston, MA

The LUNA study is a prospective, randomized, double-blind, sham-controlled, decentralized clinical trial in participants with heavy menstrual bleeding of no known structural cause. The study includes two age-based cohorts: adolescents aged 14-21 and adults aged 22-45. Participants in both cohorts will be randomized to receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN), or sham stimulation. Participants will be enrolled into the study over the course of five consecutive menstrual cycles. All study activities will occur remotely and in addition to participants' typical treatment for HMB (as allowed by the eligibility criteria). During the first two consecutive menstrual cycles (M1 - M2, "Baseline Phase"), no tAN treatment will be delivered. Participants will estimate blood loss using the Pictorial Bleeding Assessment Chart (PBAC), and menstrual cramp pain will be assessed with a Numerical Rating Scale (NRS), daily throughout the duration of the menstruation phase of their two baseline menstrual cycles. Menstrual symptoms will be assessed using the Cox Menstrual Symptom Scale (CMSS) and a general quality of life assessment will be conducted on the final day of menstruation using the RAND Short-Form 36 (RAND-36). Menstrual-related quality of life assessments will also be conducted on the final day of each menstruation using the Menstrual Bleeding Questionnaire (MBQ) in the adult cohort, and the adolescent version (aMBQ) in the adolescent cohort. During the following three consecutive menstruations (M3 - M5, "Treatment Phase"), participants will self-administer one 2-hour sham or active tAN session daily, beginning Day 1 of menstruation through the final day of menstruation in each menstrual cycle. Blood loss (via the PBAC) and menstrual cramp pain (via the NRS) will be assessed daily throughout the duration of each menstruation. Quality of life will be assessed with the CMSS, RAND-36, and the MBQ (adults) or aMBQ (adolescents) on the final day of each menstruation. A device usability survey will be completed at the end of M3 and M5. Participants will exit the study after the final day of M5.

Waitlist Available
Online Trial

Lindus Health - DECENTRALIZED STUDY

Navid Khodaparast, PhD

Spark Biomedical, Inc.

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Menstrual Cycle vs. Birth Control Pills for Protein Metabolism

18 - 40
Female
Toronto, Canada

The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle. Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons. Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body. The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.

Recruiting
Has No Placebo

Goldring Center for High Performance Sport

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Tri-Sprintec clinical trials?

We made a collection of clinical trials featuring Tri-Sprintec, we think they might fit your search criteria.
Go to Trials
Image of Center for Human Nutrition in Fayetteville, United States.

Protein Meals for Polycystic Ovary Syndrome

18 - 50
Female
Fayetteville, AR

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that improve postprandial insulin and glucose responses are central to managing metabolic symptoms in PCOS. Meals higher in protein can attenuate postprandial glycemia and enhance satiety, but the effects may vary by protein source. Animal sources of protein typically have higher essential amino acid content and insulinogenic potential, whereas plant proteins offer fiber and phytochemicals that may influence glycemic dynamics differently. Few studies have directly compared the acute metabolic effects of plant versus animal protein in women with PCOS. Given the distinct pathophysiology of PCOS, extrapolating findings from healthy populations may be misleading. Understanding protein-specific effects on postprandial insulin, glucose, and appetite-regulating hormones in this group is essential for targeted nutrition guidance. Additionally, plant-based diets are increasingly promoted for cardiometabolic health, but their acute effects in insulin-resistant women remain underexplored. This study will assess whether plant and animal protein meals elicit differential postprandial responses in women with PCOS. Findings may inform dietary recommendations aimed at improving metabolic outcomes in this high-risk population.

Recruiting
Has No Placebo

Center for Human Nutrition

Jamie I Baum, PhD

Image of William J. Hybl Sports Medicine and Performance Center in Colorado Springs, United States.

Moderate Aerobic Exercise for Menstrual Symptoms

18 - 40
Female
Colorado Springs, CO

The goal of this clinical trial is to evaluate the impact of moderate aerobic exercise on menstrual symptom management in sedentary women both using and not using hormonal contraceptives. The main questions it aims to answer are: Is there a reduction in physical and/or psychological menstrual cycle related symptom burden with participation in moderate aerobic exercise for sedentary women using and not using hormonal contraceptives? Is there a difference in physical and/or psychological menstrual cycle related symptom burden between hormonal contraceptive and non-hormonal contraceptive users? Is a moderate aerobic exercise intervention more effective in reducing physical and/or psychological menstrual related symptom burden for sedentary women using or not using hormonal contraceptives? Participants will: * Have their body composition assessed using dual energy X-ray absorptiometry pre and post exercise intervention. * Complete a Menstrual Symptom Index (MSi) to report daily menstrual cycle related symptom burden in addition to the Premenstrual Symptom Screening Tool (PSST) and Heavy Menstrual Bleeding (HMB) questionnaire monthly. * Utilize an at-home monitor to test urinary luteinizing hormone, estrone-3-glucuronide, and pregnanediol glucuronide approximately 10 times per month and report menstrual cycle length. * Record physical activity habits by continuously wearing a wrist-based accelerometer and chest-strap heart rate monitor during planned aerobic exercise sessions and complete the International Physical Activity Questionnaire (IPAQ) monthly. * Maintain their usual sedentary activity habits for one menstrual cycle followed by completion of an exercise intervention designed to progress individuals to meet minimum recommended aerobic physical activity guidelines of 150 minutes per week set by the American College of Sports Medicine for two menstrual cycles.

Recruiting
Has No Placebo

William J. Hybl Sports Medicine and Performance Center

Have you considered Tri-Sprintec clinical trials?

We made a collection of clinical trials featuring Tri-Sprintec, we think they might fit your search criteria.
Go to Trials
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Tri-Sprintec clinical trials?

We made a collection of clinical trials featuring Tri-Sprintec, we think they might fit your search criteria.
Go to Trials